Design and organization of the Cilostazol Stroke Prevention Study

Journal of Stroke and Cerebrovascular Diseases

Volumn 9, Issue 1, 2000, Pages 36-44

  Gotoh, Fumio ^a,b,m   Ohashi, Yastlo ^a,b   Tohgi, Hideo ^c,l   Hirai, Shunsaku ^d,l,m   Terasi, Akiro ^e,m   Fukuuchi, Yasuo ^a,l,m   Ohtomo, Eiichi ^f   Shinohara, Yukito ^g,l,m   Itoh, Eiichi ^h,n   Matsuda, Tamotsu ^i,n   Sawada, Tohru ^j,l,o   Yamaguchi, Takenori ^j,l,o   Nishimaru, Katsuya ^k,l   Terashi, Akiro ^l   Tashiro, Kunio ^l   Urasawa, Kiichi ^l   Kogure, Hisaya ^l   Itoyama, Yasuto ^l   Aoki, Nobuo ^m   Yamazaki, Hiroo ^m   Maruyama, Shyouichi ^m   Otomo, Eiichi ^m   Tazaki, Yoshiaki ^m   Takahashi, Akira ⁿ   Yasunaga, Koichiro ^o   Yanagisawa, Takehiko ^o   Takahashi, Kazuo ^l   Kuramoto, Jun ^l   Nakamuara, Shigenobu ^l   Fujishima, Masatoshi ^l   Osame, Mitsuhiro ^l   Maekawa, Tatsuro ^p   Sakai, Fumihiko ^q   Yamada, Nobuhiro ^r   Sato, Toshiya ^s   more..

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d GUNMA UNIVERSITY   (Japan)

^e NIPPON MEDICAL SCHOOL   (Japan)

^f Yokufukai Geriatric Hospital   (Japan)

^g TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Meito ku   (Japan)

ⁱ KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^j NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^k FUKUOKA UNIVERSITY   (Japan)

^l Otsuka Pharmaceutical Co Ltd ^*  (Japan)

^m Kitasato University ^*  (Japan)

ⁿ Tokyo University ^*  (Japan)

^o Institute of Statistical Mathematics ^*  (Japan)

^p OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^q KITASATO UNIVERSITY   (Japan)

^r UNIVERSITY OF TOKYO   (Japan)

^s INSTITUTE OF STATISTICAL MATHEMATICS   (Japan)

more..

Author keywords

Cilostazol; Double blind test; Protocol; Secondary stroke prevention

Indexed keywords

CILOSTAZOL;

ARTICLE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK;

EID: 0033754567     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-3057(00)38264-7     Document Type: Article

References (22)

1. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography
2. Pharmacological manipulation of tissue cyclic AMP by inhibitors: Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells
3. Effect of cilostazol on platelet aggregation and experimental thrombosis
4. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells
5. Effect of cilostazol on experimental cerebral infarction in rabbits
6. Effect of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia
7. AICLA controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia
8. The Canadian American Tidopidine Study (CATS) in thromboembolic stroke
9. Swedish Aspirin Low-Dose Trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
10. A randomized trial of aspirin and sulfinpyrazone in threatened stroke
11. Controlled trial of aspirin in cerebral ischemia
12. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Interim results
13. High-dose acetylsalicylic acid after cerebral infarction
14. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
15. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
16. The study of cerebral infarction: Special reference to anti-platelet drug
17. Benefits and hazards of antiplatelet therapy in ischemic cerebrovascular diseases
18. Secondary prevention of vascular disease by prolonged antiplatelet treatment
19. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo
20. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint
21. A multiple testing procedure for clinical trials
22. Benefits and hazards of antiplatelet therapy in ischemic cerebrovascular diseases